Abstract | OBJECTIVE: It was the aim of this study to analyze the clinical value of the determination of serum S-100beta protein in high-risk melanoma patients. PATIENTS AND METHODS: RESULTS: Ninety-seven patients were included in the study. Median follow-up was 62.9 months (range 32.7-87.4). High baseline S-100beta levels were associated with positive lymph node status (p = 0.02). High S-100beta levels (during therapy) showed a relation with positive lymph node status (p = 0.014), number of positive lymph nodes (p = 0.01), macroscopic lymph node involvement (p = 0.002) and second melanoma diagnosis at study entry (p = 0.001). By univariate analysis, high baseline S-100beta levels were associated with disease-free survival (p = 0.004) and overall survival (p = 0.0007). Similarly, high S-100beta levels during therapy were associated with disease-free survival (p < 0.0001) and overall survival (p < 0.0001). In the multivariate analysis, high S-100beta levels during therapy (hazard ratio 1.017, 95% CI 1.008-1.026; p < 0.0001) and high baseline S-100beta levels (hazard ratio 3.31, 95% CI 1.10-9.89; p = 0.032) were independent prognostic factors for overall survival when compared with low levels while on therapy and low baseline S-100beta levels, respectively. CONCLUSIONS: These results provide evidence of the clinical usefulness of serum S-100beta level determination in high-risk melanoma patients. S-100beta serum determination should be considered to be included in clinical trials that test adjuvant therapies in melanoma patients.
|
Authors | Josep Domingo-Domènech, Teresa Castel, Josep Maria Auge, Xabier Adrian Garcia-Albeniz, Carles Conill, Susana Puig, Ramon Vilella, Jose Matas, Josep Malvehy, Pere Gascón, Begoña Mellado, Rafael Molina |
Journal | Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine
(Tumour Biol)
Vol. 28
Issue 5
Pg. 264-72
( 2007)
ISSN: 1423-0380 [Electronic] Netherlands |
PMID | 17962723
(Publication Type: Journal Article)
|
Copyright | Copyright (c) 2007 S. Karger AG, Basel. |
Chemical References |
- Biomarkers, Tumor
- Immunologic Factors
- Interferon alpha-2
- Interferon-alpha
- Nerve Growth Factors
- Recombinant Proteins
- S100 Calcium Binding Protein beta Subunit
- S100 Proteins
|
Topics |
- Adult
- Aged
- Biomarkers, Tumor
(blood)
- Combined Modality Therapy
- Disease-Free Survival
- Female
- Humans
- Immunologic Factors
(therapeutic use)
- Interferon alpha-2
- Interferon-alpha
(therapeutic use)
- Kaplan-Meier Estimate
- Male
- Melanoma
(blood, drug therapy, mortality, pathology, surgery)
- Middle Aged
- Neoplasm Staging
- Nerve Growth Factors
(blood)
- Prognosis
- Prospective Studies
- Recombinant Proteins
- Risk
- S100 Calcium Binding Protein beta Subunit
- S100 Proteins
(blood)
- Skin Neoplasms
(blood, drug therapy, mortality, pathology, surgery)
- Survival Analysis
- Treatment Outcome
|